ANDA 78194, held by Sun Pharmaceutical Industries. Paroxetine Hydrochloride.
As of Nov 21, 2026, ANDA 78194 (Paroxetine Hydrochloride), held by Sun Pharmaceutical Industries, was first approved by FDA on Jun 29, 2007, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 29, 2007 | Original application | Approved | None posted |
| Paroxetine HydrochlorideEQ 10MG BASE · tablet;oral | Paroxetine Hydrochloride | Discontinued |
| Paroxetine HydrochlorideEQ 20MG BASE · tablet;oral | Paroxetine Hydrochloride | Discontinued |
| Paroxetine HydrochlorideEQ 30MG BASE · tablet;oral | Paroxetine Hydrochloride | Discontinued |
| Paroxetine HydrochlorideEQ 40MG BASE · tablet;oral | Paroxetine Hydrochloride | Discontinued |
| Jul 14, 2017 | Supplement 12Manufacturing | Approved | None posted |
| Jul 14, 2017 | Supplement 13Labeling · Standard review | Approved | None posted |
| Jul 14, 2017 | Supplement 14Labeling · Standard review | Approved | None posted |
| Mar 11, 2009 | Supplement 6Labeling | Approved | None posted |
| Dec 15, 2008 | Supplement 4Labeling | Approved | None posted |
| May 29, 2008 | Supplement 2Labeling | Approved | None posted |
| Jun 29, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters